CLAIMS

We claim:

- 1. A method for increasing the potency of an amide-linked or ester-linked local 1
- 2 anesthetic in a patient comprising the step of,
- administering at least one methanesulfonamide compound with an amide-linked or 3
- ester-linked local anesthetic or combination thereof. 4
- 1 2. The method of claim 1 wherein said amide-linked local anesthetic is selected from the
- 2 group consisting of dibucaine, articaine, levobupivacaine, ropivacaine, todocaine, lidocaine,
- 3 prilocaine, mepivacaine, bupivacaine, and etidocaine.
- 3. The method of claim 1 wherein said ester-linked local anesthetic is selected from the 1
- group consisting of procaine, chloroprocaine, benzocaine, butamben, picrate, cocaine, and
- tetracaine.
 - 4. The method of claim 1 further comprising the step of administering a vasoconstrictive
- substance to said patient.
 - 5. The method of claim 4 wherein said vasoconstrictive substance is selected from the group
 - consisting of epinephrine and levonordefrin.
 - 1 6. The method of claim 1 wherein said at least one methanesulfonamide compound is
 - 2 selected from the group consisting of ibutilide, sotalol, E4031, dofetilide and sematilide.
 - 1 7. A method of providing local anesthesia to a patient in need thereof, comprising the step of
 - 2 administering to said patient at least one amide-linked or ester-linked local anesthetic
 - 3 together with at least one methanesulfonamide compound.
 - 8. The method of claim 7 wherein said at least one amide-linked local anesthetic is selected 1
 - 2 from the group consisting of dibucaine, articaine, levobupivacaine, ropivacaine, todocaine,
 - 3 lidocaine, prilocaine, mepivacaine, bupivacaine, and etidocaine.

- 9. The method of claim 7 wherein said at least one ester-linked local anesthetic is selected
- 2 from the group consisting of procaine, chloroprocaine, benzocaine, butamben, picrate,
- 3 cocaine, and tetracaine.
- 1 10. The method of claim 7 further comprising the step of administering a vasoconstrictive
- 2 substance to said patient.
- 1 11. The method of claim 10 wherein said vasoconstrictive substance is selected from the
- 2 group consisting of epinephrine and levonordefrin.
- 1 12. The method of claim 7 wherein said at least one methanesulfonamide compound is
- 2 selected from the group consisting of ibutilide, solatol, E4031, dofetilide and sematilide.
- 1 13. A pharmaceutical composition comprising,
 - at least one amide-linked or ester-linked local anesthetic, and
 - at least one methanesulfonamide compound.
- 1 14. The pharmaceutical composition of claim13 further comprising a vasoconstrictive
- 2 substance.
- 1 15. The method of claim 14 wherein said vasoconstrictive substance is selected from the
- 2 group consisting of epinephrine and levonordefrin.
- 1 16. The pharmaceutical composition of claim 13 wherein said at least one amide-linked local
- 2 anesthetic is selected from the group consisting of dibucaine, articaine, levobupivacaine,
- 3 ropivacaine, todocaine, lidocaine, prilocaine, mepivacaine, bupivacaine, and etidocaine.
- 1 17. The pharmaceutical composition of claim 13 wherein said at least one ester-linked local
- 2 anesthetic is selected from the group consisting of procaine, chloroprocaine, benzocaine,
- 3 butamben, picrate, cocaine, and tetracaine.

- 1 18. The pharmaceutical composition of claim 13 wherein said at least one
- 2 methanesulfonamide compound is selected from the group consisting of ibutilide, solatol,
- 3 E4031, dofetilide and sematilide.